Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Morgan

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|November 27, 2020
An increase in multi-site practices: The shifting paradigm for gynecologic cancer care deliveryKatherine Hicks-Courant, Genevieve P Kanter, Robert L Giuntoli, et al.
The Lancet. Oncology|December 25, 2012
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyJohn Farley, William E Brady, Vinod Vathipadiekal, et al.
Gynecologic Oncology Reports|March 4, 2022
Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER studyDaniel H Saris, Anna Jo Bodurtha Smith, Colleen Brensinger, et al.
JCI Insight|February 23, 2018
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12Mireia Uribe-Herranz, Kyle Bittinger, Stavros Rafail, et al.
Cancer Immunology, Immunotherapy : CII|October 25, 2011
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionChristina S Chu, Jean Boyer, Daniel S Schullery, et al.
Gynecologic Oncology|October 4, 2016
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyPeter G Rose, James J Java, Mark A Morgan, et al.
Gynecologic Oncology|June 9, 2019
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancerKathleen N Moore, Camille C Gunderson, Paul Sabbatini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2022
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)Janos L Tanyi, Leslie M Randall, Setsuko K Chambers, et al.
JCI Insight|June 22, 2023
H2Bub1 loss is an early contributor to clear cell ovarian cancer progressionAdam J Ferrari, Priyanka Rawat, Hannah S Rendulich, et al.
Cancer Cell|October 10, 2018
Integrated Analysis of Genetic Ancestry and Genomic Alterations across CancersJiao Yuan, Zhongyi Hu, Brandon A Mahal, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|November 27, 2020
An increase in multi-site practices: The shifting paradigm for gynecologic cancer care deliveryKatherine Hicks-Courant, Genevieve P Kanter, Robert L Giuntoli, et al.
The Lancet. Oncology|December 25, 2012
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyJohn Farley, William E Brady, Vinod Vathipadiekal, et al.
Gynecologic Oncology Reports|March 4, 2022
Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER studyDaniel H Saris, Anna Jo Bodurtha Smith, Colleen Brensinger, et al.
JCI Insight|February 23, 2018
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12Mireia Uribe-Herranz, Kyle Bittinger, Stavros Rafail, et al.
Cancer Immunology, Immunotherapy : CII|October 25, 2011
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionChristina S Chu, Jean Boyer, Daniel S Schullery, et al.
Gynecologic Oncology|October 4, 2016
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyPeter G Rose, James J Java, Mark A Morgan, et al.
Gynecologic Oncology|June 9, 2019
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancerKathleen N Moore, Camille C Gunderson, Paul Sabbatini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2022
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)Janos L Tanyi, Leslie M Randall, Setsuko K Chambers, et al.
JCI Insight|June 22, 2023
H2Bub1 loss is an early contributor to clear cell ovarian cancer progressionAdam J Ferrari, Priyanka Rawat, Hannah S Rendulich, et al.
Cancer Cell|October 10, 2018
Integrated Analysis of Genetic Ancestry and Genomic Alterations across CancersJiao Yuan, Zhongyi Hu, Brandon A Mahal, et al.
Pageof 9